Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Xience V Everolimus-Eluting Coronary Stent

American Journal of Cardiology

Volumn 102, Issue 12, 2008, Pages 1624-1630

  Torguson, Rebecca ^a   Waksman, Ron ^a  

^a Washington Hospital Center   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS;

BIOCOMPATIBILITY; CLINICAL EVALUATION; CORONARY STENT; DEVICE THERAPY; DRUG ELUTING STENT; FOOD AND DRUG ADMINISTRATION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; SAFETY;

ADVISORY COMMITTEES; DEVICE APPROVAL; DRUG-ELUTING STENTS; EQUIPMENT SAFETY; EVALUATION STUDIES AS TOPIC; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; SIROLIMUS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 57649106008     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.08.013     Document Type: Review

References (19)

1. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., et al., TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
2. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., et al., RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
3. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
4. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
5. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
6. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., Kaiser C., and BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
7. Lopez-Minguez J.R., Nogales J.M., Morales A., Alonso R., Gonzalez R., and Merchan A. Clinical and angiographic follow-up in patients with Cypher or Taxus stents in populations with high percentage of trial-excluded lesions. Cardiovasc Revasc Med 6 (2005) 92-98
8. Roy P., Buch A.N., Javaid A., Okabe T., Raya V., Pinto Slottow T.L., Steinberg D.H., Smith K., Xue Z., Gevorkian N., et al. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Am J Cardiol 101 (2008) 293-299
9. Roy P., Okabe T., Pinto Slottow T.L., Steinberg D.H., Smith K., Torguson R., Xue Z., Gevorkian N., Satler L.F., Kent K.M., et al. Correlates of clinical restenosis following intracoronary implantation of drug-eluting stents. Am J Cardiol 100 (2007) 965-969
10. Cosgrave J., Agostoni P., Ge L., Iakovou I., Chieffo A., Biondi-Zoccai G.G., Sangiorgi G.M., Montorfano M., Michev I., Airoldi F., et al. Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions. Am J Cardiol 96 (2005) 1663-1668
11. Boam A., and Kozeli D. Guidance for industry coronary drug-eluting stents-nonclinical and clinical studies. http://www.fda.gov/cdrh/ode/guidance/6255comp.pdf Accessed May 2, 2008
12. Johnson G, Simhambhatla M, Coleman L, Stone G, Krucoff M, Sudhir K. Xience V everolimus-eluting coronary stent system: Abbott Vascular presentation. Presented at: FDA Circulatory System Device Panel meeting; November 29, 2007; Gaithersburg, Maryland. Available at: http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4333s1-02%20-FDA%20Presentation%20v3.pdf. Accessed May 2, 2008.
13. Agler H, Fiorentino R, Yan X, Duggirala H. Xience V everolimus-eluting coronary stent system: FDA review. Presented at: FDA Circulatory System Device Panel meeting; November 29, 2007; Gaithersburg, Maryland.
14. Serruys P.W., Ong A.T.L., Piek J., Neumann F.-J., van der Giessen W.J., Wiemer M., Zeiher A., Grube E., Haase J., Thuesen L., et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT FIRST trial. EuroIntervention 1 (2005) 58-65
15. Stone G.W., Midei M., Newman W., Sanz M., Hermiller J.B., Williams J., Farhat N., Mahaffey K.W., Cutlip D.E., Fitzgerald P.J., et al., SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299 (2008) 1903-1913
16. Ellis S.G., Colombo A., Grube E., Popma J., Koglin J., Dawkins K.D., and Stone G.W. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 49 (2007) 1043-1051
17. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
18. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
19. Pocock S.J., Lansky A.J., Mehran R., Popma J.J., Fahy M.P., Na Y., Dangas G., Moses J.W., Pucelikova T., Kandzari D.E., et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 51 (2008) 23-32